

Table 5.6d
Immunosuppression Use for Maintenance by Regimen
Prior to Discharge, 2000 to 2009
Recipients with Kidney Transplants

	Transplant Year									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Functioning Graft at Discharge	13,116	13,823	14,324	14,691	15,543	16,012	16,670	16,260	16,129	16,485
With Immunosuppression Info	12,897	13,798	14,260	14,619	15,411	15,793	16,470	16,027	16,037	16,293
CyA	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%	0.1%	0.0%	0.0%
Tac	0.6%	1.1%	2.0%	1.0%	1.3%	1.4%	1.9%	1.5%	1.6%	1.9%
--- + MMF/MPA	0.1%	0.1%	0.2%	0.4%	0.4%	0.5%	0.5%	0.4%	0.9%	0.9%
CyA + MMF/MPA	0.9%	0.9%	0.7%	1.6%	1.7%	1.3%	2.0%	1.9%	0.8%	0.5%
Tac + MMF/MPA	1.1%	1.7%	2.9%	6.6%	13.7%	19.8%	24.4%	27.6%	28.4%	27.7%
--- + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%
Tac + OtherAntimet	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
--- + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Siro/Evero	0.1%	0.3%	0.1%	0.2%	0.4%	0.2%	0.0%	0.1%	0.1%	0.1%
CyA + Siro/Evero	0.1%	0.1%	0.4%	0.9%	1.2%	1.2%	1.1%	0.9%	0.8%	0.7%
Tac + Siro/Evero	0.4%	1.2%	1.3%	1.7%	1.9%	1.1%	1.0%	0.6%	0.3%	0.1%
--- + MMF/MPA + Siro/Evero	0.1%	0.2%	0.2%	0.4%	0.6%	0.4%	0.5%	0.2%	0.2%	0.3%
CyA + MMF/MPA + Siro/Evero	0.1%	0.2%	0.2%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + Siro/Evero	0.1%	0.2%	0.3%	1.2%	0.7%	0.5%	0.4%	0.2%	0.2%	0.2%
--- + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Steroids	1.2%	1.0%	0.9%	1.3%	1.7%	1.3%	0.5%	0.3%	0.4%	0.7%
CyA + Steroids	3.1%	1.7%	1.2%	1.4%	1.4%	0.4%	0.3%	0.3%	0.1%	0.2%
Tac + Steroids	3.5%	3.9%	3.3%	2.3%	2.5%	2.3%	1.7%	2.0%	1.7%	2.8%
--- + MMF/MPA + Steroids	1.6%	1.4%	1.2%	1.6%	1.6%	2.0%	2.6%	2.0%	1.8%	1.4%
CyA + MMF/MPA + Steroids	37.0%	27.6%	22.9%	18.3%	14.2%	9.9%	6.7%	5.6%	4.5%	3.5%
Tac + MMF/MPA + Steroids	31.4%	38.5%	46.2%	46.8%	46.6%	50.3%	49.2%	51.9%	54.4%	56.0%
--- + OtherAntimet + Steroids	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Steroids	3.6%	2.2%	0.8%	0.4%	0.2%	0.1%	0.1%	0.1%	0.1%	0.0%
Tac + OtherAntimet + Steroids	1.1%	1.3%	1.1%	0.9%	0.5%	0.2%	0.3%	0.2%	0.3%	0.3%
--- + Siro/Evero + Steroids	0.5%	0.5%	0.4%	0.6%	0.4%	0.2%	0.1%	0.1%	0.1%	0.0%
CyA + Siro/Evero + Steroids	5.0%	3.6%	2.8%	2.2%	1.3%	1.2%	1.2%	0.9%	0.8%	0.4%
Tac + Siro/Evero + Steroids	4.4%	6.4%	4.8%	4.7%	3.5%	2.4%	2.9%	0.9%	0.4%	0.1%
Other Regimen	3.7%	5.5%	5.9%	4.9%	3.7%	3.1%	2.5%	2.0%	2.2%	2.0%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.